NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Planned

Publication
Article
OncologyONCOLOGY Vol 14 No 4
Volume 14
Issue 4

The National Institutes of Health (NIH) is sponsoring a Consensus Development Conference on Adjuvant Therapy for Breast Cancer, to be held in Bethesda, Maryland, on November 1-3, 2000.

The National Institutes of Health (NIH) is sponsoring a Consensus Development Conference on Adjuvant Therapy for Breast Cancer, to be held in Bethesda, Maryland, on November 1-3, 2000.

The conference will focus on new data on chemotherapy, hormonal therapy, and other aspects of treatment that have emerged over the past decade since the last consensus conference, and will culminate in the formulation of recommendations for clinical practice.

During the conference, a panel of experts (from outside of the NIH) will hear presentations from leading researchers and then consider questions on specific topics, such as the selection of chemotherapy, radiation therapy, and hormonal therapy. The agenda will also include the clinical use of prognostic markers and quality-of-life issues. Both node-negative and node-positive breast cancers will be discussed.

Health professionals, researchers, patient advocates, and other members of the public may register to attend the by sending an e-mail to breastcancer@prospectassoc.com or by going to the NIH web site for consensus conferences found at http://odp.od.nih.gov/consensus. Additional information is available by calling (301) 592-3320.

Recent Videos
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content